SOURCE: Frontiers in Aging Neuroscience. 14 (no pagination), 2022. Article Number: 1036676.
DATE OF PUBLICATION: 24 Oct 2022.
AUTHORS: Zheng W.; Zhang X.-Y.; Xu R.; Huang X.; Zheng Y.-J.; Huang X.-B.; Li Z.-Z.; Chen H.-D.
ABSTRACT
OBJECTIVE: We performed this systemic review to investigate the therapeutic potential and safety of adjunctive accelerated repetitive transcranial magnetic stimulation (aTMS) for older patients with depression.
METHOD(S): We included published randomized clinical trials (RCTs) and observational studies targeting adjunctive aTMS for older patients with depression.
RESULT(S): Two open-label self-controlled studies (n = 29) fulfilled the criteria for inclusion. The included studies reported significant improvements in depressive symptoms from baseline to post-aTMS (all Ps < 0.05). One study reported a dropout rate of 10.5% (2/19). Mild headache was the most common adverse reaction.
CONCLUSION(S): The currently available evidence from two open-label self-controlled studies indicates that adjunctive aTMS is a safe and effective therapy for older patients with depression.
